Ardelyx
Open
$6.30
Prev. Close
$6.30
High
$6.30
Low
$6.29
Market Snapshot
$1.46B
-23.7
-0.16
$333.62M
489
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 489 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
emptyResult
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 489 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Recently from Cashu
Calm markets shift focus to biotech catalysts; Ardelyx faces clinical and funding headwinds
Market calm shifts attention to biotech catalysts Clinical and funding headwinds for Ardelyx A muted early-morning market tone is shifting investor attention away from headline macro moves and onto co…
Missing Source Material Delays Biotech Summaries — Ardelyx Communications Gap Highlights Need for Timely Releases
Unclear source halts routine company summaries for biotech coverage A reader asks for an article titled “Companies Reporting Before The Bell” but provides no text or link, and requests guidance on len…
Missing Source Material Disrupts Automated Biotech Briefings, Risks Ardelyx Communication Accuracy
Missing Source Material Hampers Automated Briefing for Mid‑Sized Biotechs Context of the request A user seeking an automated summary notifies a news service that they have only supplied a headline — “…
Lack of primary documents hinders Ardelyx coverage and accurate reporting
Ardelyx coverage stalls without primary source material Biotechnology reporting and corporate communications rely on access to source documents, and the absence of those documents is constraining time…